SCHEMBL6157484

SCHEMBL6157484

Cc1cc(NC(=O)NN(c2ccccc2)c2cccc(CN)c2)ccc1N1CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
KDM4E B2RXH2 4/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
DGAT1 O75907 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
CSF1R P07333 1/20 0.41
KIT P10721 1/20 0.41
PDGFRA P16234 1/20 0.41
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
FLT3 P36888 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK10 P53779 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 3/20 0.41
NPC1 O15118 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6157574 0.91 ALDH1A1 (0.41) ALDH1A1KDM4EGAAHPGDSMN1; SMN2
SCHEMBL6156558 0.90 RAB9A (0.52) ALDH1A1HPGDSMN1; SMN2CYP3A4CYP2C19
SCHEMBL6156914 0.85 F10 (0.49) ALDH1A1HPGDDGAT1SMN1; SMN2CSF1R
SCHEMBL6156431 0.84 HTT (0.48) ALDH1A1KDM4EHPGDDGAT1SMN1; SMN2
SCHEMBL6158842 0.82 KMT2A (0.38) ALDH1A1GAAHPGDSMN1; SMN2CYP1A2
SCHEMBL6156652 0.82 F10 (0.38) GAAHPGDSMN1; SMN2LMNANPC1
SCHEMBL6157199 0.81 F10 (0.43)
SCHEMBL6157230 0.81 MAPT (0.48) ALDH1A1KDM4EGAAHPGDSMN1; SMN2
SCHEMBL6156453 0.79 F10 (0.45) SMN1; SMN2LMNANPC1RAB9AMAPT
SCHEMBL6157122 0.77 F10 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US claimed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP claimed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO claimed
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US disclosed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP disclosed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases SERPINC1, F11, F12 ALDH1A1 212/4885KDM4E 2273/4885GAA 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.